Investigational Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Trial ID:
IRB-16-6770
Marin Xavier, MD
This is a phase 2, randomized, open label study evaluating the safety and efficacy of denintuzumab mafodotin plus rituximab, ifosfamide, carboplatine, and etoposide (RICE) chemotherapy vs RICE in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant.

Inclusion Criteria

  • - Have histologically confirmed relapsed or refractory DLBCL and grade 3b follicular lymphoma

Exclusion Criteria

  • - Have a history of Progressive Multifocal Leukoencephalopathy (PML)

Contact Info:

  • Shannon Cyhan
  • cyhan.shannon@scrippshealth.org
  • 619-849-4469